Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 85 results for menopause

  1. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  2. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

  3. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  4. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  5. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  6. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  7. Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment (HTG760)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.

  8. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)

    Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.

  9. Patient decision aids

    Long term heartburn treatment Gynaecological conditions and abortion Menopause: HRT and the likelihood of some medical conditions - a...

  10. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence (TA1086)

    Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

  11. EDI roadmap and annual action plan

    NICE's equality, diversity, and inclusion roadmap and annual action plan - committed to creating a forward-looking, positive work culture where everyone can thrive.

  12. Key question: responsive

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  13. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  14. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  15. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.